Physician profile
Paul Leva
NPI 1841222577
$12,326.86
in general payments reported to CMS, 2019-2025
46 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,314 · 2021: $1,661 · 2022: $2,046 · 2023: $1,872 · 2024: $2,159 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,623 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,623.17 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,308.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,180.19 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,039.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $780.75 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $700.51 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $590.85 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $531.03 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Merz North America, INC. | $424.02 | 2021-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $409.97 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $401.57 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $382.67 | 2019-2025 | |
| Apyx Medical Corporation | $358.33 | 2019-2020 | |
| Boston Scientific Corporation | $265.34 | 2022-2023 | |
| Pfizer INC. | $258.60 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $219.73 | 2019-2023 | Livalo, Seglentis |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Leva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.